Home / Health / China Approves Amgen's New Lung Cancer Drug
China Approves Amgen's New Lung Cancer Drug
11 Apr
Summary
- China approved Amgen's tarlatamab for hard-to-treat lung cancer.
- The drug targets adults with small cell lung cancer resistant to chemotherapy.
- Tarlatamab could generate over $2 billion in annual sales for Amgen.
Amgen's targeted immunotherapy, tarlatamab, has received approval from China's National Medical Products Administration. This development was announced by its partner, BeOne Medicines. The drug is designed for adults battling extensive-stage small cell lung cancer that has proven resistant to prior chemotherapy treatments.
Known as Imdelltra in the United States, tarlatamab represents a key innovation in Amgen's bispecific antibody pipeline. These antibodies work by connecting cancer cells with immune cells, thereby enabling the body's own immune system to combat the disease. While launch details and pricing for the Chinese market remain undisclosed, analysts project tarlatamab could achieve annual sales surpassing $2 billion for Amgen.
